Veeva Systems Inc. and Sarah Cannon Research Institute Enter Strategic Partnership to Enhance Oncology Clinical Trials

Reuters

04 Jun

<a href="https://laohu8.com/S/VEEV">Veeva Systems Inc.</a> and Sarah Cannon Research Institute Enter Strategic Partnership to Enhance Oncology Clinical Trials

Veeva Systems Inc. has entered into a strategic collaboration with the Sarah Cannon Research Institute (SCRI) to enhance the efficiency and speed of oncology clinical trials. By adopting the Veeva Clinical Platform, SCRI aims to unify its contract research organization $(CRO.AU)$ and site management organization (SMO) on a single platform, ensuring seamless data flow across its more than 200 research site locations. This partnership marks a significant innovation in oncology research, allowing SCRI to standardize operations, automate key processes, and streamline trial delivery. The integration of Veeva's platform is expected to empower SCRI's clinical teams to deliver groundbreaking therapies with greater precision and speed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veeva Systems Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF02659) on June 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2540502320"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540502320\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540502320?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540502320","market":"us","top_or_hot":-1,"title":"Veeva Systems Inc. and Sarah Cannon Research Institute Enter Strategic Partnership to Enhance Oncology Clinical Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VEEV\">Veeva Systems Inc.</a> and Sarah Cannon Research Institute Enter Strategic Partnership to Enhance Oncology Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Veeva Systems Inc. has entered into a strategic collaboration with the Sarah Cannon Research Institute (SCRI) to enhance the efficiency and speed of oncology clinical trials. By adopting the Veeva Clinical Platform, SCRI aims to unify its contract research organization <a href=\"https://laohu8.com/S/CRO.AU\">$(CRO.AU)$</a> and site management organization (SMO) on a single platform, ensuring seamless data flow across its more than 200 research site locations. This partnership marks a significant innovation in oncology research, allowing SCRI to standardize operations, automate key processes, and streamline trial delivery. The integration of Veeva's platform is expected to empower SCRI's clinical teams to deliver groundbreaking therapies with greater precision and speed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veeva Systems Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF02659) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veeva Systems Inc. and Sarah Cannon Research Institute Enter Strategic Partnership to Enhance Oncology Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeeva Systems Inc. and Sarah Cannon Research Institute Enter Strategic Partnership to Enhance Oncology Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-04 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VEEV\">Veeva Systems Inc.</a> and Sarah Cannon Research Institute Enter Strategic Partnership to Enhance Oncology Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Veeva Systems Inc. has entered into a strategic collaboration with the Sarah Cannon Research Institute (SCRI) to enhance the efficiency and speed of oncology clinical trials. By adopting the Veeva Clinical Platform, SCRI aims to unify its contract research organization <a href=\"https://laohu8.com/S/CRO.AU\">$(CRO.AU)$</a> and site management organization (SMO) on a single platform, ensuring seamless data flow across its more than 200 research site locations. This partnership marks a significant innovation in oncology research, allowing SCRI to standardize operations, automate key processes, and streamline trial delivery. The integration of Veeva's platform is expected to empower SCRI's clinical teams to deliver groundbreaking therapies with greater precision and speed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veeva Systems Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF02659) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL8mwJhD:1","article_id":"2540502320","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540502320","pubTimestamp":1749034999,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Veeva Systems Inc. has entered into a strategic collaboration with the Sarah Cannon Research Institute  to enhance the efficiency and speed of oncology clinical trials. By adopting the Veeva Clinical Platform, SCRI aims to unify its contract research organization  and site management organization  on a single platform, ensuring seamless data flow across its more than 200 research site locations. This partnership marks a significant innovation in oncology research, allowing SCRI to standardize operations, automate key processes, and streamline trial delivery. The integration of Veeva's platform is expected to empower SCRI's clinical teams to deliver groundbreaking therapies with greater precision and speed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Veeva Systems Inc.与Sarah Cannon研究所建立战略合作伙伴关系以加强肿瘤临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCA":0.9,"VEEV":0.9},"content_text":"Veeva Systems Inc. and Sarah Cannon Research Institute Enter Strategic Partnership to Enhance Oncology Clinical Trials\n    \n\n        Veeva Systems Inc. has entered into a strategic collaboration with the Sarah Cannon Research Institute (SCRI) to enhance the efficiency and speed of oncology clinical trials. By adopting the Veeva Clinical Platform, SCRI aims to unify its contract research organization $(CRO.AU)$ and site management organization (SMO) on a single platform, ensuring seamless data flow across its more than 200 research site locations. This partnership marks a significant innovation in oncology research, allowing SCRI to standardize operations, automate key processes, and streamline trial delivery. The integration of Veeva's platform is expected to empower SCRI's clinical teams to deliver groundbreaking therapies with greater precision and speed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veeva Systems Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF02659) on June 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}